(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 January 2022 (06.01.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/003421 A2

(51) International Patent Classification:
A61K 31/7048 (2006.01)

(21) International Application Number:
PCT/IB2021/000451

(22) International Filing Date:
30 June 2021 (30.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/046,335 30 June 2020 (30.06.2020) US
63/046,322 30 June 2020 (30.06.2020) US

(71) Applicant: **REDHILL BIOPHARMA LTD.** [IL/IL]; 21 Ha'arba'a St., Tel-aviv (IL).

(72) Inventors: **FATHI, Reza**; 21 Ha'arba'a St., Tel-aviv (IL). **RADAY, Gilead**; 21 Ha'arba'a St., Tel-aviv (IL). **ANDERSON, Patricia**; 21 Ha'arba'a St., Tel-aviv (IL). **OFFMAN, Elliot**; 21 Ha'arba'a St., Tel-aviv (IL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2022/003421 A2

(54) **Title:** TRIPLE ANTIBIOTIC FIXED-DOSE COMBINATION PRODUCTS, DOSING REGIMEN, METHODS, AND KITS FOR TREATING PULMONARY NON-TUBERCULOSIS MYCOBACTERIAL INFECTIONS

(57) **Abstract:** A fixed-dose combination drug product formulated for oral delivery comprises a fixed 158.3 mg dose of clarithromycin, a fixed 13.3 mg dose of clofazimine and a fixed 40.0 mg dose of rifabutin. The fixed-dose combination drug product is sufficiently designed for use in treating pulmonary *Mycobacterium avium* Complex (MAC) disease in a subject in need thereof. A method for treating MAC disease in a human having MAC lung infection comprising orally administering, twice daily, about 475 mg of clarithromycin, about 40 mg of clofazimine and about 120 mg of rifabutin. A kit for treating pulmonary MAC disease in an individual having MAC lung infection comprises a supply of fixed-dose combination drug products, wherein each of the fixed-dose combination drug products comprise a fixed 158.3 mg dose of clarithromycin, a fixed 13.3 mg dose of clofazimine and a fixed 40.0 mg dose of rifabutin; and instructions for use.